Table 1 Demographic and clinical characteristics of patients with recurrent angioedema (RAE) (n = 86) as well as their response to treatment and quality of life impairment as assessed by use of the Thai Angioedema Quality of Life questionnaire (AE-QoL), the Thai Dermatology Life Quality Index (DLQI), the Patient Global Assessment of Quality of Life (PGA-QoL)
From: Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change
Values | ||||
|---|---|---|---|---|
Gender, n (%) | ||||
Female | 69 (80.2%) | |||
Male | 17 (19.8%) | |||
Diagnosis, n (%) | ||||
RAE without wheals | 10 (11.6%) | |||
RAE with wheals | 76 (88.0%) | |||
Range of scores (total score) | ||||
Thai AE-QoL | 0–79.4 (100) | |||
Thai DLQI | 0–23 (30) | |||
PGA-QoL | 0–3 (4) | |||
Disease severity of urticaria of 76 RAE patients with wheals | ||||
Urticaria activity score over 7 days (UAS7), n (%) | ||||
Urticaria-free (UAS7 = 0) | 18 (23.7%) | |||
Well-controlled CSU (UAS7 = 1–6) | 13 (17.1%) | |||
Mild activity CSU (UAS7 = 7–15) | 26 (34.2%) | |||
Moderate activity CSU (UAS7 16–27) | 14 (18.4%) | |||
Severe activity CSU (UAS7 = 28–42) | 5 (6.6%) | |||
Treatment, n (%) | ||||
H1-antihistamines | 74 (86.0%) | |||
H1-antihistamines + prednisolone | 8 (9.3%) | |||
H1-antihistamines + omalizumab | 4 (4.7%) | |||
Impairment of health-related quality of life using: | ||||
- PGA-QoL questionnaire, n (%) | AE-QoL total value mean ± SD (median) | 1st quartile | 3rd quartile | |
None | 11.2 ± 14.2 (5.9) | 0 | 19.1 | 35 (40.7%) |
Mild | 29.9 ± 13.2 (32.4) | 20.6 | 38.2 | 31 (36.0%) |
Moderate | 49.3 ± 17.6 (52.2) | 34.9 | 67.3 | 12 (14.0%) |
Severe | 46.9 ± 20.4 (42.6) | 34.6 | 61.8 | 8 (9.3%) |
Very severe | 0 | 0 | 0 | 0 (0.0%) |
- DLQI questionnaire, n (%) | ||||
No effect | 11.6 ± 13.6 (5.9) | 0 | 19.9 | 33 (38.4%) |
Small effect | 26.0 ± 15.3 (24.3) | 16.9 | 34.6 | 22 (25.6%) |
Moderate effect | 39.7 ± 17.3 (38.2) | 33.1 | 49.3 | 13 (15.1%) |
Very large effect | 42.2 ± 19 (42.6) | 35.7 | 61.8 | 18 (20.9%) |
Extremely large effect | 0 | 0 | 0 | 0 (0.0%) |